Leber congenital amaurosis 02

Narfström K et al. (1989) The Briard dog: a new animal model of congenital stationary night blindness.

Wrigstad A et al. (1994) Slowly progressive changes of the retina and retinal pigment epithelium in Briard dogs with hereditary retinal dystrophy. A morphological study.

Marlhens F et al. (1997) Mutations in RPE65 cause Leber's congenital amaurosis.

Morimura H et al. (1998) Mutations in the RPE65 gene in patients with autosomal recessive retinitis pigmentosa or leber congenital amaurosis.

Aguirre GD et al. (1998) Congenital stationary night blindness in the dog: common mutation in the RPE65 gene indicates founder effect.

Yzer S et al. (2003) A Tyr368His RPE65 founder mutation is associated with variable expression and progression of early onset retinal dystrophy in 10 families of a genetically isolated population.

Al-Khayer K et al. (2004) Thirty-year follow-up of a patient with leber congenital amaurosis and novel RPE65 mutations.

WAARDENBURG PJ et al. (1963) ON VARIOUS RECESSIVE BIOTYPES OF LEBER'S CONGENITAL AMAUROSIS.

Chung DC et al. (2009) Leber congenital amaurosis: clinical correlations with genotypes, gene therapy trials update, and future directions.

Maguire AM et al. (2008) Safety and efficacy of gene transfer for Leber's congenital amaurosis.

Bainbridge JW et al. (2008) Effect of gene therapy on visual function in Leber's congenital amaurosis.

Hauswirth WW et al. (2008) Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial.

Cideciyan AV et al. (2008) Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics.

Cideciyan AV et al. (2009) Vision 1 year after gene therapy for Leber's congenital amaurosis.

Maguire AM et al. (2009) Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial.

OMIM.ORG article